EGFR and non-small cell lung carcinoma: We also detected Topo IIα in paired tissues from patients with EGFRm NSCLC receiving EGFR-TKI treatment, including osimertinib, and found that Topo IIα levels were in general significantly elevated after relapse from the treatment compared with their baseline levels (Figure 5C).